Winton Group’s VolitionRx Ltd VNRX Stock Holding History

Winton Group’s Portfolio VNRX Stock Details VNRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-939	Closed	-$60K	–	1523
2020 Q3	$60K	Buy	+939	New	+$63.8K	﹤0.01%	1438

Other funds holding VNRX

LIM

Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Winton Group's VNRX Position: Q4 2020 in Review

Winton Group sold out of VolitionRx Ltd (VNRX) in Q4 2020, closing a stake of 939 shares — an estimated $60K sold.

Winton Group first reported a position in VNRX in Q3 2020 and held it in 1 quarter. The position peaked at $60K in Q3 2020. 45 funds tracked by Wall St. Rank hold VNRX as of Q4 2020.

Winton Group reported no remaining VolitionRx Ltd position as of Q4 2020 after selling out during the quarter.
Winton Group sold 939 VolitionRx Ltd shares in Q4 2020, an estimated $60K.
Winton Group first reported a position in VolitionRx Ltd in Q3 2020 and held it in 1 quarter.
Winton Group's VolitionRx Ltd position peaked at $60K in Q3 2020.
45 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q4 2020.

Based on Winton Group's 13F filing for Q4 2020, filed 12 Feb 2021.